Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2025
0mins
Should l Buy ?
Source: Business Insider
Financial Overview: As of December 31, 2024, Turnstone Biologics Corp. reported cash, cash equivalents, and short-term investments totaling $28.9 million.
Company Developments: Turnstone Biologics has been downgraded to Neutral from Overweight due to challenges with TIL therapy and has decided to halt all clinical studies while exploring strategic alternatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
